For example, preclinical studies show RHO-associated RP treatment after murine phenotype onset (P21–P28) shows no benefit, and PDE6A-associated RP treatment at P14 is less effective than P0–P3. The gene discussed is RHO; the disease is retinitis pigmentosa 1.